GB9501178D0
(en)
*
|
1995-01-20 |
1995-03-08 |
Wellcome Found |
Guanine derivative
|
ATE254463T1
(de)
*
|
1996-01-19 |
2003-12-15 |
Glaxo Group Ltd |
Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung
|
IT1283447B1
(it)
*
|
1996-07-18 |
1998-04-21 |
Ind Chimica Srl |
Processo di preparazione del valaciclovir e relativi intermedi
|
CN1250449A
(zh)
*
|
1997-01-17 |
2000-04-12 |
味之素株式会社 |
新型z-伐昔洛韦结晶
|
GB0010446D0
(en)
*
|
2000-04-28 |
2000-06-14 |
Glaxo Wellcome Kk |
Pharmaceutical formulation
|
SI1368349T1
(sl)
*
|
2001-02-24 |
2007-06-30 |
Boehringer Ingelheim Pharma |
Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
|
US6849736B2
(en)
*
|
2001-09-07 |
2005-02-01 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of valacyclovir hydrochloride
|
WO2003040145A1
(en)
*
|
2001-11-05 |
2003-05-15 |
Glaxo Group Limited |
Anhydrous crystal form of valaciclovir hydrochloride
|
CN1307177C
(zh)
*
|
2001-11-14 |
2007-03-28 |
特瓦制药工业有限公司 |
伐昔洛韦的合成与纯化
|
US20060147519A1
(en)
*
|
2002-06-24 |
2006-07-06 |
Ashish Gogia |
Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US20050043329A1
(en)
*
|
2002-09-06 |
2005-02-24 |
Shlomit Wizel |
Crystalline forms of valacyclovir hydrochloride
|
US20050059684A1
(en)
*
|
2002-10-16 |
2005-03-17 |
Ben-Zion Dolitzky |
Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
|
AU2003277433A1
(en)
*
|
2002-10-16 |
2004-05-04 |
Teva Pharmaceutical Industries Ltd. |
Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
|
AU2003289995A1
(en)
*
|
2002-12-09 |
2004-06-30 |
Texcontor Etablissement |
Anhydrous crystalline form of valacyclovir hydrochloride
|
WO2004106338A1
(en)
*
|
2003-05-30 |
2004-12-09 |
Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. |
Novel crystalline forms of valacyclovir hydrochloride
|
WO2005000850A2
(en)
*
|
2003-06-02 |
2005-01-06 |
Teva Pharmaceutical Industries, Ltd. |
Novel crystalline forms of valacyclovir hydrochloride
|
JP2007522130A
(ja)
*
|
2004-01-21 |
2007-08-09 |
テバ ファーマシューティカル インダストリーズ リミティド |
塩酸バラシクロビルの調製方法
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
CN1976933A
(zh)
*
|
2004-06-30 |
2007-06-06 |
特瓦制药工业有限公司 |
减少晶体盐酸伐昔洛韦中的残留醇的方法
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
US20060178512A1
(en)
*
|
2005-02-04 |
2006-08-10 |
Cheruthur Govindan |
Method for preparing amino acid esters of nucleoside analogues
|
EP1891071B1
(en)
*
|
2005-05-25 |
2012-02-22 |
Eli Lilly And Company |
Cyclopropanecarboxylate esters of acyclovir
|
EP1746098A1
(en)
|
2005-07-21 |
2007-01-24 |
SOLMAG S.p.A. |
Valacyclovir polymorphs and a process for the preparation thereof
|
DE102005035891A1
(de)
*
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US20070112193A1
(en)
*
|
2005-11-14 |
2007-05-17 |
Khunt Mayur D |
Valacyclovir process
|
CA2873524C
(en)
|
2006-05-04 |
2018-02-20 |
Boehringer Ingelheim International Gmbh |
A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
CN1903854B
(zh)
*
|
2006-08-09 |
2012-05-23 |
丽珠医药集团股份有限公司 |
一种合成盐酸伐昔洛韦的方法
|
US20080167325A1
(en)
*
|
2006-12-27 |
2008-07-10 |
Bs Praveen Kumar |
Valacyclovir compositions
|
US20080281099A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Mayur Devjibhai Khunt |
Process for purifying valacyclovir hydrochloride and intermediates thereof
|
GB0710277D0
(en)
*
|
2007-05-30 |
2007-07-11 |
Univ Birmingham |
Use of antivirals in the treatment of medical disorders
|
EP3542801A1
(en)
*
|
2007-08-17 |
2019-09-25 |
Boehringer Ingelheim International GmbH |
Purin derivatives for use in the treatment of fap-related diseases
|
JPWO2009031576A1
(ja)
*
|
2007-09-03 |
2010-12-16 |
味の素株式会社 |
バラシクロビル塩酸塩結晶の製造方法
|
US20090076039A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched valacyclovir
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
MY164581A
(en)
*
|
2008-08-15 |
2018-01-15 |
Boehringer Ingelheim Int |
Purin derivatives for use in the treatment of fab-related diseases
|
CA2736421A1
(en)
|
2008-09-10 |
2010-03-18 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
NZ592924A
(en)
|
2008-12-23 |
2014-05-30 |
Boehringer Ingelheim Int |
Salt forms of a xanthine derivative
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
EA034869B1
(ru)
|
2009-11-27 |
2020-03-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
|
AU2011249722B2
(en)
|
2010-05-05 |
2015-09-17 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
WO2011158252A1
(en)
|
2010-06-15 |
2011-12-22 |
Matrix Laboratories Ltd |
Process for the preparation of valacyclovir hydrochloride polymorphic form ii
|
KR20200028498A
(ko)
|
2010-06-24 |
2020-03-16 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 요법
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
CN102584825B
(zh)
*
|
2011-01-17 |
2014-04-02 |
四川科伦药物研究有限公司 |
一种合成盐酸伐昔洛韦的方法
|
WO2013010964A1
(en)
|
2011-07-15 |
2013-01-24 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
EP2852592A4
(en)
*
|
2011-11-25 |
2015-12-23 |
Piramal Entpr Ltd |
PROCESS FOR THE PREPARATION OF VALACYCLOVIR CHLORHYDRATE
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
|
US20130303554A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in sirs and/or sepsis
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
JP6615109B2
(ja)
|
2014-02-28 |
2019-12-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dpp−4阻害薬の医学的使用
|
JP2019517542A
(ja)
|
2016-06-10 |
2019-06-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
リナグリプチンおよびメトホルミンの組合せ
|
CN110437231B
(zh)
*
|
2019-09-04 |
2022-04-29 |
上药康丽(常州)药业有限公司 |
一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
|
US20230218644A1
(en)
|
2020-04-16 |
2023-07-13 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|